Design and Synthesis of Novel 5-Substituted Acyclic Pyrimidine Nucleosides as Potent and Selective Inhibitors of Hepatitis B Virus
Authors:
- 9 April 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (10) , 2032-2040
Abstract
A novel class of 5-substituted acyclic pyrimidine nucleosides, 1-[(2-hydroxyethoxy)methyl]-5-(1-azidovinyl)uracil (9a), 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]-5-(1-azidovinyl)uracil (9b), and 1-[4-hydroxy-3-(hydroxymethyl)-1-butyl]-5-(1-azidovinyl)uracil (9c), were synthesized by regiospecific addition of bromine azide to the 5-vinyl substituent of the respective 5-vinyluracils (2a−c) followed by treatment of the obtained 5-(1-azido-2-bromoethyl) compounds (3a−c) with t-BuOK, to affect the base-catalyzed elimination of HBr. Thermal decomposition of 9b and 9c at 110 °C in dioxane yielded corresponding 5-[2-(1-azirinyl)]uracil analogues (10b,c). The 5-(1-azidovinyl)uracil derivatives 9a−c were found to exhibit potent and selective in vitro anti-HBV activity against duck hepatitis B virus (DHBV) infected primary duck hepatocytes at low concentrations (EC50 = 0.01−0.1 μg/mL range). The most active anti-DHBV agent (9c), possessing a [4-hydroxy-3-(hydroxymethyl)-1-butyl] substituent at N-1, exhibited an activity (EC50 of 0.01−0.05 μg/ mL) comparable to that of reference compound (−)-β-l-2‘,3‘-dideoxy-3‘-thiacytidine (3-TC) (EC50 = 0.01−0.05 μg/mL). In contrast, related 5-[2-(1-azirinyl)]uracil analogues (10b,c) were devoid of anti-DHBV activity, indicating that an acyclic side chain at C-5 position of the pyrimidine ring is essential for anti-HBV activity. The pyrimidine nucleosides (9a−c, 10b,c) exhibited no cytotoxic activity against a panel of 60 human cancer cell lines. All of the compounds investigated did not show any detectable toxicity to several stationary and proliferating host cell lines or to mitogen stimulated proliferating human T lymphocytes, up to the highest concentration tested.Keywords
This publication has 25 references indexed in Scilit:
- Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 2001
- Does immunoglobulin interfere with the immunogenicity to Pasteur Mérieux inactivated hepatitis A vaccine?Journal of Hepatology, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovirAntiviral Research, 1995
- Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatmentJournal of Hepatology, 1995
- Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapyLiver International, 1994
- Metabolic and pharmacokinetic studies following oral administration of14C-famciclovir to healthy subjectsXenobiotica, 1994
- Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2′-deoxy-2′-fluoro-β-d-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2′-deoxyuridineAntiviral Research, 1984
- Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediateCell, 1982
- Bromohydrin formation in dimethyl sulfoxideJournal of the American Chemical Society, 1968